Gold prices slip lower; consolidating after recent gains
SOUTH SAN FRANCISCO - Senti Biosciences, Inc. (NASDAQ:SNTI), a biotech firm specializing in gene therapy with a market capitalization of $84.17 million, announced the appointment of Feng Hsiung to its Board of Directors. Hsiung, a seasoned executive with a background in business, finance, and investment, joins the board with a wealth of experience from various industries. His appointment, effective March 7, 2025, is expected to bring valuable insights as the company pursues its strategic goals and seeks long-term growth. According to InvestingPro analysis, the company currently shows signs of being slightly undervalued at current levels.
Hsiung is the founder and CEO of Acion Partners, an investment advisory with ties to KKR, and has previously led York Capital’s Asia operations. He is also the President of Raising Investment Corporation, a family-owned enterprise in logistics. Hsiung’s educational credentials include a B.A. from Dartmouth College.
In addition to the board appointment, Senti Bio granted stock options to three new employees on March 7, 2025. The options, totaling 202,700 shares, were issued under the company’s 2022 Inducement Equity Plan, with a per-share exercise price of $3.52, close to the current trading price of $3.21. The stock has shown significant volatility, trading between $1.52 and $16.94 over the past 52 weeks. Jay Cross, the new Chief Financial Officer, received the majority of these options.
Senti Bio focuses on creating advanced cell and gene therapies through its Gene Circuit platform. The company’s pipeline includes therapies for both liquid and solid tumors, with its lead candidate, SENTI-202, showing promising initial clinical results. With an EBITDA of -$52.96 million in the last twelve months and a beta of 2.53, indicating higher volatility than the broader market, Senti Bio continues to explore the potential of its Gene Circuits in various therapeutic areas and maintains partnerships to further its research and development efforts. InvestingPro subscribers can access 8 additional key insights about SNTI’s financial health and growth prospects.
The forward-looking statements included in the press release reflect the management’s current expectations and are subject to risks and uncertainties. These statements are not guarantees of future performance and may differ significantly from actual results. With the next earnings announcement scheduled for March 21, 2025, investors can find comprehensive financial analysis and detailed metrics on InvestingPro. The company’s progress and achievements are subject to various factors, including industry competition, regulatory changes, and clinical trial outcomes.
This news article is based on a press release statement from Senti Biosciences, Inc.
In other recent news, Senti Biosciences, Inc. has announced several key developments. The company secured stockholder approval for the amendment and restatement of its 2022 Equity Incentive Plan, adding 4,300,000 shares to incentivize employees, consultants, and directors. This approval also allows for the conversion of Series A convertible preferred stock and the exercise of warrants to purchase common stock, which was ratified by a significant majority. Additionally, Senti Biosciences has appointed Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations. Cross will oversee financial strategy and investor relations, while Siddiqui will manage process development and manufacturing. In another leadership change, Feng Hsiung has joined the board, and Brenda Cooperstone has resigned from the Audit Committee but remains on the board. The company also announced an additional $10 million investment through private placement equity financing, raising the total to $47.6 million. These funds will support the development of Senti Bio’s SENTI-202 program and other operational activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.